N-BOC-4-甲基-4-羟基哌啶 | 406235-30-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-BOC-4-甲基-4-羟基哌啶
• 中文别名: 4-羟基-4-甲基哌啶-1-羧酸叔丁酯；1-BOC-4-羟基-4-甲基哌啶
• 英文名称: tert-butyl 4-hydroxy-4-methylpiperidine-1-carboxylate
• 英文别名: 4-hydroxy-4-methyl-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-hydroxy-4-methylpiperidin-1-carboxylate
• CAS: 406235-30-1
• 化学式: C₁₁H₂₁NO₃
• mdl: MFCD04972471
• 分子量: 215.293
• InChiKey: SWUCHJAQBNXPBO-UHFFFAOYSA-N

物化性质

• 沸点：
  296.4±33.0 °C(Predicted)
• 密度：
  1.075±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥环境中使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Boc-4-Hydroxy-4-methylpiperidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Boc-4-Hydroxy-4-methylpiperidine
CAS number: 406235-30-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H21NO3
Molecular weight: 215.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用
N-BOC-4-甲基-4-羟基哌啶可作为有机合成中间体和医药中间体，主要用于实验室研发过程和化工生产过程中。

化学性质
白色粉末，在常温常压下稳定，应避免与强氧化剂接触。

反应信息

• 作为反应物：
  描述：

  N-BOC-4-甲基-4-羟基哌啶 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 4-甲基-4-羟基哌啶
  参考文献：
  名称：

  FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS

  摘要：

  该披露提供了由化学式I或其药用可接受的盐、溶剂化合物、多型体、酯、互变异构体或前药表示的新型化合物。这些化合物可用作Trk的抑制剂，并且在治疗疼痛、癌症、炎症、神经退行性疾病和某些传染病方面是有用的。 在化合物I的某些化合物中，Q为—CH═CR3C(O)NR4R5，—C≡CC(O)NR4R5，或...

  公开号：

  US20160168156A1
• 作为产物：
  描述：

  1-Boc-4-甲基-4-哌啶甲酸 在 lithium tetrafluoroborate 、 12-phenyl-12H-benzo[b]phenothiazine 、 水 作用下， 以 丙酮 为溶剂， 反应 24.0h， 以65%的产率得到N-BOC-4-甲基-4-羟基哌啶
  参考文献：
  名称：

  有机光氧化还原催化脱羧 C(sp3)-O 键形成

  摘要：

  这份手稿报告了一种可见光介导的有机硫化物催化，它能够使简单的脂肪醇与叔或仲烷基羧酸衍生的氧化还原活性酯之间脱羧偶联，以产生 C(sp3)-OC(sp3) 片段。还描述了使用其他杂原子亲核试剂（例如水、酰胺和硫醇）进行偶联的结果。

  DOI：

  10.1021/jacs.9b12335

文献信息

• A Noncoordinating Acid–Base Catalyst for the Mild and Nonreversible <i>tert</i>-Butylation of Alcohols and Phenols
  作者：Keith R. Fandrick、Nitinchandra D. Patel、Suttipol Radomkit、Arindom Chatterjee、Stefan Braith、Daniel R. Fandrick、Carl A. Busacca、Chris H. Senanayake

  DOI：10.1021/acs.joc.1c00193

  日期：2021.3.19

  A mild and nonreversible tert-butylation of alcohols and phenols can be achieved in high yields using the noncoordinating acid–base catalyst [bis(trifluoromethane)sulfonimide and 2,6-lutidine] with a tert-butylation reagent, tert-butyl 2,2,2-trichloroacetimidate. This method allows the use of substrates containing acid sensitive groups such as ketal, Boc, and boronate esters.

  温和和不可逆的叔醇和酚的-butylation可以以高产率使用非配位酸-碱催化剂[双（三氟甲烷）磺酰亚胺和2,6-二甲基吡啶]用来实现叔-butylation试剂，叔丁基2,2- ，2-三氯乙亚胺酸酯。该方法允许使用包含酸敏感基团的底物，例如缩酮，Boc和硼酸酯。
• [EN] PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] COMPOSES DE PYRAZINE COMME INHIBITEURS DE PHOSPHODIESTERASE 10
  申请人：AMGEN INC

  公开号：WO2010057121A1

  公开（公告）日：2010-05-20

  Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡嗪化合物、含有它们的组合物以及制备这些化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
• A General Method for Photocatalytic Decarboxylative Hydroxylation of Carboxylic Acids
  作者：Shah Nawaz Khan、Muhammad Kashif Zaman、Ruining Li、Zhankui Sun

  DOI：10.1021/acs.joc.0c00312

  日期：2020.4.3

  A general and practical method for decarboxylative hydroxylation of carboxylic acids was developed through visible light-induced photocatalysis using molecular oxygen as the green oxidant. The addition of NaBH4 to in situ reduce the unstable peroxyl radical intermediate much broadened the substrate scope. Different sp3 carbon-bearing carboxylic acids were successfully employed as substrates, including

  通过使用分子氧作为绿色氧化剂的可见光诱导的光催化作用，开发了一种用于羧酸脱羧羟基化的通用方法。原位添加NaBH 4可以减少不稳定的过氧自由基中间体，大大扩大了底物的范围。不同的含sp 3碳的羧酸已成功地用作底物，包括苯乙酸型底物以及脂肪族羧酸。该转化在伯，仲和叔羧酸上可以顺利进行。
• [EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS BENZÈNESULFONAMIDES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2017201468A1

  公开（公告）日：2017-11-23

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

  本发明涉及苯磺酰胺化合物，包括它们的立体异构体、对映异构体、互变异构体或其混合物；或用于治疗与电压门控钠通道相关的疾病或病症的药用可接受盐、溶剂化物或前药，例如癫痫。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE RÉPLICATION DU VIRUS D'IMMUNODÉFICIENCE HUMAINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014028384A1

  公开（公告）日：2014-02-20

  The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该公开涉及到式(I)的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该公开提供了HIV的新型抑制剂，包含这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。